centerforbiosimilars12h
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Gary Fanjiang, MD, MBA, MS
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Courtney Flaherty
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Amanda Forys, MSPH
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH
Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
centerforbiosimilars2d
Robert Rifkin, MD, FACP
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Mike Gladstone
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Switching From Ustekinumab to Biosimilar SB17 Maintains Efficacy, Safety in Patients With Psoriasis
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...
centerforbiosimilars3d
Jeff Baldetti, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4d
Eye on Pharma: Teva, Formycon, Celltrion Biosimilar Updates in Global Markets
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...